Watch an interview with the Director of UPMC Clinical Test Development Laboratory, Dr. Aatur Singhi, on Pittsburgh Today Live, as they discuss the importance of early testing and detection when fighting Pancreatic Cancer.
Watch an interview with the Director of UPMC Clinical Test Development Laboratory, Dr. Aatur Singhi, on Pittsburgh Today Live, as they discuss the importance of early testing and detection when fighting Pancreatic Cancer.
NEW YORK – In a prospective study of more than 1,800 patients at 31 clinical centers in the US, the PancreaSeq test developed at the University of Pittsburgh surpassed currently used guidelines for correctly classifying potentially cancerous pancreatic cysts.
PITTSBURGH —A molecular test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, according to a large, multi-center study led by University of Pittsburgh School of Medicine and UPMC researchers.
PancreaSeq is a product of the Molecular & Genomic Pathology Laboratory at the University of Pittsburgh Medical Center.